Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment
Autore:
Ambrosetti, U; Donde, E; Piatti, G; Cappellini, MD;
Indirizzi:
Univ Milan, Osped Maggiore, IRCCS, Dept Otolaryngol, Milan, Italy Univ Milan Milan Italy Maggiore, IRCCS, Dept Otolaryngol, Milan, Italy Univ Milan, Osped Maggiore, IRCCS, Inst Resp Dis, Milan, Italy Univ MilanMilan Italy ped Maggiore, IRCCS, Inst Resp Dis, Milan, Italy Univ Milan, Osped Maggiore, IRCCS, Ctr Anemie Congenite, Milan, Italy UnivMilan Milan Italy giore, IRCCS, Ctr Anemie Congenite, Milan, Italy Univ Milan, Osped Maggiore, IRCCS, Dept Internal Med, Milan, Italy Univ Milan Milan Italy Maggiore, IRCCS, Dept Internal Med, Milan, Italy
Titolo Testata:
PHARMACOLOGICAL RESEARCH
fascicolo: 5, volume: 42, anno: 2000,
pagine: 485 - 487
SICI:
1043-6618(200011)42:5<485:AEIABM>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
PIG IN-VIVO; GENTAMICIN OTOTOXICITY; IRON-CHELATION; DEFEROXAMINE; DESFERRIOXAMINE; NEUROTOXICITY; THERAPY;
Keywords:
beta-thalassemia; ototoxicity; sensorineural hearing loss; desferrioxamine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Ambrosetti, U Via Pinturicchio 5, I-20133 Milan, Italy Via Pinturicchio 5Milan Italy I-20133 -20133 Milan, Italy
Citazione:
U. Ambrosetti et al., "Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment", PHARMAC RES, 42(5), 2000, pp. 485-487

Abstract

With the improved life expectation of beta -thalassemia major patients, new clinical problems, such as hearing damage, must be evaluated. Fifty-seven patients (32 F, 25 M; age range 17-32 years) have been studiedto define risk factors for development of sensorineural hearing loss. All patients with beta -thalassemia major received daily chelation therapywith subcutaneous injection of desferrioxamine (30-50 mg kg(-1) per day). We performed an otological visit and pure tone audiometry as well as impedance; patients were followed for 3 years. Four patients with a conductive hearing loss were excluded; 66.6% had a normal audiogram; 22.8% had a slight sensorineural deficit (less than or equal to 35 dB HL) with high frequency losses; only two patients (3.5%) had a moderate deficit (between 35 and 75 dB HL). In normal subjects ABR recordinggave normal values. There was no association between age, ferritin level, therapeutic index (T. I.) and hearing loss. We conclude that no significant difference exists between beta -thalassemic patients and non-thalassemic subjects of the same age; desferrioxamine treatment seem to be non-ototoxic when employed at the present dosages, but the ototoxicity is probably related to individual susceptibility that is unforeseeable; in any case, the risk of ototoxicity seems to be much less than the benefits which derive from the use of this drug. (C) 2000 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 22:24:30